Simpson Thacher represented GTCR in connection with its simultaneous signing and closing of a strategic, structured minority investment in Solmetex, a leading provider of dental products, systems, and consumables such as amalgam separation, waterline safety solutions, dental isolation technology, and regenerative biomaterials. The staged investment structure, with potential funding of up to $200 million, will support the acceleration of Solmetex's expansion strategy through both organic growth, leveraging the Company's current product portfolio and solutions, as well as through strategic value-enhancing acquisitions.
Solmetex provides amalgam separation solutions to over 85,000 dental offices across the United States. Through the acquisition and integration of complementary products, Solmetex has expanded its portfolio to include solutions for dental waterline treatment and maintenance, modern dental isolation solutions and regenerative biomaterials.
GTCR is focused on investing in transformative growth in companies in the business & consumer services, financial services & technology, healthcare and technology, media & telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in approximately 300 companies, and the firm currently manages approximately $50 billion in equity capital.
The Simpson Thacher team includes Katherine Krause, Elizabeth Cooper, Iliana Karaoglan and David Krieghbaum (M&A); Sunny Cheong and Catherine Ciriello (Capital Markets); Russell Light and Shareef Salfity (Tax); Adam Moss (Credit); Gregory Grogan, Linda Barrett, Scott Schilson and Margaret Wang (Executive Compensation and Employee Benefits); Lori Lesser, James Talbot, Amy Candido and Tally Smitas (Intellectual Property); Vanessa Burrows and Jacob Madden (Healthcare Regulatory); and Kelly Karapetyan (Antitrust).